We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

152 hedge funds and large institutions have $414M invested in Enanta Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 68 increasing their positions, 33 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 13

106% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 33

12% more funds holding

Funds holding: 136 → 152 (+16)

14% less capital invested

Capital invested by funds: $483M → $414M (-$68.5M)

19% less call options, than puts

Call options by funds: $1.63M | Put options by funds: $2M

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
152
Holders Change
+16
Holders Change %
+11.76%
% of All Funds
4.05%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
31
Increased
68
Reduced
33
Closed
13
Calls
$1.63M
Puts
$2M
Net Calls
-$373K
Net Calls Change
+$6.9M

Top Buyers

1
EC
EcoR1 Capital
California
+$6.69M
2
SAM
Senzar Asset Management
New York
+$4.87M
3
GAM
Gotham Asset Management
New York
+$2.47M
4
NI
Numeric Investors
Massachusetts
+$2.45M
5
AL
AJO LP
Pennsylvania
+$2.44M

Top Sellers

1
Invesco
Invesco
Georgia
-$16.1M
2
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$11.1M
3
O
OrbiMed
New York
-$7.1M
4
MVM
McClain Value Management
Connecticut
-$4.14M
5
WRF
Waddell & Reed Financial
Kansas
-$3.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCP
26
Seizert Capital Partners
Michigan
$3.46M +$491K +17,640 +18%
MVM
27
McClain Value Management
Connecticut
$3.13M -$4.14M -148,719 -58%
QI
28
QS Investors
New York
$2.82M +$136K +4,900 +5%
RFC
29
Russell Frank Company
Washington
$2.75M +$572K +20,552 +28%
Principal Financial Group
30
Principal Financial Group
Iowa
$2.67M +$125K +4,504 +5%
TCIM
31
TIAA CREF Investment Management
New York
$2.61M +$859K +30,840 +53%
GAM
32
Gotham Asset Management
New York
$2.6M +$2.47M +88,631 New
NI
33
Numeric Investors
Massachusetts
$2.59M +$2.45M +88,144 New
AL
34
AJO LP
Pennsylvania
$2.58M +$2.44M +87,716 New
LCM
35
Landscape Capital Management
New Jersey
$2.5M +$1.29M +46,415 +119%
TCM
36
Tieton Capital Management
Washington
$2.5M -$244K -8,748 -9%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$2.44M +$1.44M +51,880 +167%
CCMH
38
Cornerstone Capital Management Holdings
New York
$2.43M +$1.39M +50,000 +152%
Wells Fargo
39
Wells Fargo
California
$2.38M -$234K -8,391 -9%
BBA
40
Baker Bros. Advisors
New York
$2.21M – – –
SIM
41
Spark Investment Management
New York
$2.14M +$2.03M +72,800 New
SSCM
42
Summit Street Capital Management
New York
$2.1M +$2M +71,675 New
Invesco
43
Invesco
Georgia
$2.05M -$16.1M -578,804 -89%
Deutsche Bank
44
Deutsche Bank
Germany
$1.94M -$1.88M -67,610 -51%
BIM
45
BlackRock Investment Management
Delaware
$1.87M +$33.7K +1,209 +2%
Ameriprise
46
Ameriprise
Minnesota
$1.8M +$48.9K +1,756 +3%
LPL Financial
47
LPL Financial
California
$1.74M +$603K +21,648 +58%
USAA
48
United Services Automobile Association
Texas
$1.71M – – –
Renaissance Technologies
49
Renaissance Technologies
New York
$1.63M +$1.55M +55,600 New
FIM
50
Freedom Investment Management
Connecticut
$1.51M +$186K +6,689 +15%
1
2
3 4 5

ENTA Hedge Fund Activity: Q1 2016 in Review

152 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2016, worth a combined $414M — down 14% from $483M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ENTA positions and 13 closed out — a net gain of 18 holders — while 68 added to existing stakes and 33 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $6.69M. The largest seller was Invesco, cutting an estimated $16.1M.

  • 152 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2016, up from 136 in Q4 2015.
  • Funds reported $414M of Enanta Pharmaceuticals stock for Q1 2016, down 14% quarter-over-quarter.
  • 31 funds opened new Enanta Pharmaceuticals positions in Q1 2016 and 13 closed out, a net change of +18 holders.
  • The largest Enanta Pharmaceuticals buyer in Q1 2016 was EcoR1 Capital, an estimated $6.69M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2016 was Invesco, an estimated $16.1M sold.

Based on aggregated 13F filings for Q1 2016.